Releaf Becomes First Medical Cannabis Clinic to Earn B Corp Status

Releaf, a UK medical cannabis clinic, has become the first patient-facing cannabis clinic to earn B Corp certification, the voluntary standard the non-profit B Lab awards to companies that clear its bar for social and environmental performance. B Lab recorded the certification in June 2026, giving the clinic a reputational credential in a young market where patients still weigh which providers to trust.

The distinction matters less as a clinical milestone than as a positioning move. B Corp status is not a licence, a regulatory approval, or a measure of clinical quality. It is an assessment of how a company treats its workers, community, customers and the environment, and how it governs itself — a credential consumer brands have long used to signal values, now attached to a cannabis-prescribing business for the first time.

How Releaf scored

Releaf earned an overall B Impact score of 84.0, above the 80 points a company must clear to qualify and well ahead of the 50.9 median for businesses that complete B Lab’s assessment. The score is built from five categories, and the weighting is telling: workers contributed 31.9 points, the single largest share, ahead of community at 20.5 and governance at 19.9. Environment (6.5) and customers (4.9) trailed — unsurprising for a digital clinic with a light physical footprint.

Those numbers describe an employer and a governance structure more than they describe a healthcare provider. Releaf’s clinical oversight sits with different bodies: the clinic is regulated by the Care Quality Commission and dispenses through an in-house pharmacy registered with the General Pharmaceutical Council. Certification also requires a company to commit, in its governing documents, to weighing all stakeholders rather than shareholders alone, and it has to be renewed rather than earned once. B Corp status sits on top of the regulatory base as a values credential, not a substitute for it.

Why a clinic pursues the credential

Medical cannabis has been legal in the UK since 2018, but NHS access stayed narrow, and most patients who want treatment go through private clinics that compete on price, product supply and trust. That last factor is where a certification like this earns its keep. The UK’s private prescription market has grown quickly, and imports have roughly doubled year over year, pulling in new clinics and sharpening the fight for patients.

Releaf’s scale gives the credential something to stand on. B Lab’s record lists more than 27,000 active patients, over 50 specialist prescribers, and a Trustpilot rating of 4.8 from more than 8,000 reviews — the volume-based trust proxy the clinic has leaned on until now. Its corporate registration describes the business model more bluntly than its marketing does: at Companies House, Releaf Dispensary Ltd — incorporated in May 2022 — is classified not as a healthcare provider but as a web portal. This is a healthtech company that happens to prescribe medicine, and B Lab slotted it under technology-based support services accordingly.

Founder Mason Soiza framed the certification as outside validation, arguing that in a sector still proving its legitimacy, an independent review of the business carries more weight than anything the company says about itself. That is the commercial logic in plain terms: in a market short on established brands, a third-party stamp is a cheaper trust signal than years of track record.

The “first” is narrower than it sounds

Releaf is not the first cannabis-linked company to carry the B Corp mark. CBD and hemp product makers have held the certification for years, and the movement now counts more than 10,700 businesses worldwide. B Lab has historically put cannabis-sector applicants through additional disclosure review before certifying them, a legacy of the industry’s contested legal status that makes clearing the assessment a more involved exercise than it is for an ordinary consumer brand. What Releaf can claim is being the first patient-facing medical cannabis clinic to earn the mark — a real distinction, but a specific one worth keeping in proportion.

For the wider industry, the practical effect is limited. The certification changes nothing about how Releaf is regulated or what it can prescribe. What it does is hand one operator a marketing differentiator that rivals will have to weigh matching. The sector has been trying to shore up its credibility on several fronts, including efforts to widen the pool of trained UK prescribers, and a values badge is a low-cost addition to that toolkit.

Releaf says it will publish its first B Corp impact report later in July 2026, setting out targets across people, environment, community and governance. That report will indicate whether the certification reflects a durable operating model or a well-timed badge — and whether an 84 holds up once the company has to report against it.